Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
23.60
+0.50 (2.16%)
Sep 26, 2025, 5:35 PM CET
18.00%
Market Cap 951.84M
Revenue (ttm) 84.66M
Net Income (ttm) 45.91M
Shares Out 40.33M
EPS (ttm) 1.13
PE Ratio 20.91
Forward PE 2.59
Dividend n/a
Ex-Dividend Date n/a
Volume 20,963
Average Volume 15,567
Open 23.30
Previous Close 23.10
Day's Range 22.40 - 23.60
52-Week Range 16.50 - 27.80
Beta 0.15
RSI 59.69
Earnings Date Sep 23, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 183
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.